AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16214622 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional facial scanning technique using Minolta Vivid 900 laser-scanning devices
Number of subjects: 40
Study 11859207 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy and TME
Number of subjects: 656
Study 11859207 — intervention group
Group type: COMPARATOR
Intervention: TME alone
Number of subjects: 656
Study 11859207 — intervention group
Group type: EXPERIMENTAL
Intervention: Margins <= 1 mm
Number of subjects: 656
Study 11859207 — intervention group
Group type: EXPERIMENTAL
Intervention: Margins <= 2 mm
Number of subjects: 656
Study 10550151 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with ifosfamide 10 g/m², carboplatin 1200 mg/m², and etoposide 1200 mg/m² (ICE)
Number of subjects: 69
Study 10550151 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with ifosfamide, carboplatin, and etoposide (ICE)
Number of subjects: 69
Study 7598070 — intervention group
Group type: EXPERIMENTAL
Intervention: Eggs from hens fed 10% ground flaxseed
Number of subjects: 28
Study 7598070 — intervention group
Group type: EXPERIMENTAL
Intervention: Eggs from hens fed 20% ground flaxseed
Number of subjects: 28
Study 7598070 — intervention group
Group type: COMPARATOR
Intervention: Control group (0% ground flaxseed)
Number of subjects: 28
Study 2358236 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity program (15 minutes of regular physical exercise before lunch, 5 days a week)
Number of subjects: 540
Study 2358236 — intervention group
Group type: COMPARATOR
Intervention: Social games (control group, seated activities for the same time periods)
Number of subjects: 540
Study 65818 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyprogesterone-caproate (Primostat)
Number of subjects: 39
Study 65818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 65818 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyprogesterone-caproate
Number of subjects: 39
Study 31266529 — intervention group
Group type: EXPERIMENTAL
Intervention: WI plus L-TAP
Number of subjects: 108
Study 31266529 — intervention group
Group type: COMPARATOR
Intervention: WI
Number of subjects: 108
Study 27988484 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-Amodiaquine (ASAQ)
Number of subjects: 380
Study 27988484 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 380
Study 27505900 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary, client-centered fall prevention program
Number of subjects: 131
Study 27505900 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 131
Study 23585744 — intervention group
Group type: EXPERIMENTAL
Intervention: auto-titrating continuous positive airway pressure (auto-CPAP)
Number of subjects: 24
Study 23585744 — intervention group
Group type: EXPERIMENTAL
Intervention: mandibular advancement device (MAD) + nasal strip
Number of subjects: 24
Study 23585744 — intervention group
Group type: COMPARATOR
Intervention: auto-CPAP and MAD + nasal strip
Number of subjects: 24
Study 22201238 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Parents Matter! Program
Number of subjects: 1115
Study 19477655 — intervention group
Group type: EXPERIMENTAL
Intervention: Alar cinch suture combined with muco‐musculo‐periosteal V‐Y closure (ACVY)
Number of subjects: 22
Study 17825689 — intervention group
Group type: EXPERIMENTAL
Intervention: Titration group: 1 tablet of tramadol/acetaminophen 37.5/325 mg QD and 1 placebo BID for 3 days, followed by 1 active tablet BID and 1 placebo QD for 4 days, followed by 1 active tablet TID for 7 days.
Number of subjects: 250
Study 17825689 — intervention group
Group type: COMPARATOR
Intervention: Nontitration group: 1 tablet of combined tramadol 37.5 mg/acetaminophen 325 mg TID for 14 days.
Number of subjects: 250
Study 17825689 — intervention group
Group type: EXPERIMENTAL
Intervention: Titration group
Number of subjects: 250
Study 17825689 — intervention group
Group type: COMPARATOR
Intervention: Nontitration group
Number of subjects: 250
Study 17825689 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 250
Study 15278855 — intervention group
Group type: EXPERIMENTAL
Intervention: Orofacial injury patients
Number of subjects: 336
Study 15278855 — intervention group
Group type: COMPARATOR
Intervention: Elective surgery patients (control)
Number of subjects: 336
Study 11176729 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lisinopril (35.0 or 32.5 mg OD)
Number of subjects: 3164
Study 11176729 — intervention group
Group type: COMPARATOR
Intervention: Low-dose lisinopril (5.0 or 2.5 mg OD)
Number of subjects: 3164
Study 11176729 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lisinopril
Number of subjects: 3164
Study 11176729 — intervention group
Group type: COMPARATOR
Intervention: Low-dose lisinopril
Number of subjects: 3164
Study 11176729 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose strategy
Number of subjects: 3164
Study 9506648 — intervention group
Group type: EXPERIMENTAL
Intervention: GH alone
Number of subjects: 70
Study 9506648 — intervention group
Group type: EXPERIMENTAL
Intervention: GH plus OX
Number of subjects: 70
Study 9506648 — intervention group
Group type: COMPARATOR
Intervention: Historical control (no treatment)
Number of subjects: 70
Study 8155435 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketoprofen 200 mg followed by 12.5 mg h‐1 over 13 h
Number of subjects: 32
Study 8155435 — intervention group
Group type: COMPARATOR
Intervention: extradural morphine 4 mg
Number of subjects: 32
Study 3247565 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injections of purified botulinum toxin type 'A'
Number of subjects: 4
Study 3247565 — intervention group
Group type: COMPARATOR
Intervention: Saline solution injected with the same method as botulinum toxin
Number of subjects: 4
Study 31218661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 0
Study 31218661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 0
Study 31218661 — intervention group
Group type: COMPARATOR
Intervention: Tildrakizumab (after switching from etanercept)
Number of subjects: 0
Study 29698447 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 185
Study 29698447 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (absent aspirin)
Number of subjects: 185
Study 29698447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 27914515 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (Eicosapentaenoic Acid)
Number of subjects: 88
Study 27914515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 25424785 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 980
Study 25424785 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 980
Study 23719550 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-protein weight-loss diet
Number of subjects: 76
Study 23719550 — intervention group
Group type: COMPARATOR
Intervention: Standard-protein weight-loss diet
Number of subjects: 76
Study 20521975 — intervention group
Group type: EXPERIMENTAL
Intervention: Red ginseng extract powder (1 g) administered orally per week for 3 years
Number of subjects: 643
Study 20521975 — intervention group
Group type: EXPERIMENTAL
Intervention: Red ginseng extract powder (1 g) administered orally per week for 3 years (male subgroup)
Number of subjects: 643
Study 20521975 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 643
Study 17457338 — intervention group
Group type: COMPARATOR
Intervention: 0 g alcohol (control)
Number of subjects: 51
Study 15812447 — intervention group
Group type: EXPERIMENTAL
Intervention: Algal-DHA
Number of subjects: 361
Study 15812447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-DHA
Number of subjects: 361
Study 15812447 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 361
Study 12428041 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone 10mg/kg given within 6 hours of life followed by 5mg/kg/day till day 5 of life intravenously
Number of subjects: 150
Study 12428041 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbitone 5mg/kg for 5 days
Number of subjects: 150
Study 10500973 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic puncture closing device
Number of subjects: 240
Study 10500973 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 240
Study 8942463 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine at 50 mg/day
Number of subjects: 10
Study 8942463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1653594 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg, increased to 80 mg if needed after 4 weeks
Number of subjects: 490
Study 1653594 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg, increased to 200 mg if needed after 4 weeks
Number of subjects: 490
Study 6354603 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment plus nimesulide (100 mg twice daily)
Number of subjects: 45
Study 6354603 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic treatment plus placebo
Number of subjects: 45
Study 31280114 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (piano training)
Number of subjects: 0
Study 31280114 — intervention group
Group type: COMPARATOR
Intervention: Video (visuospatially demanding video game)
Number of subjects: 0
Study 31280114 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 0
Study 29846553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 5084
Study 29846553 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (Control)
Number of subjects: 5084
Study 27383413 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal hydrolaparoscopy (THL) ovarian drilling
Number of subjects: 246
Study 27383413 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic ovarian drilling (LOD)
Number of subjects: 246
Study 24170718 — intervention group
Group type: EXPERIMENTAL
Intervention: Managing Cancer And Living Meaningfully (CALM) psychotherapy
Number of subjects: 50
Study 22264664 — intervention group
Group type: EXPERIMENTAL
Intervention: O(2)/N(2)O
Number of subjects: 72
Study 22264664 — intervention group
Group type: COMPARATOR
Intervention: Air (placebo)
Number of subjects: 72
Study 20961784 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-antiretroviral therapy
Number of subjects: 1571
Study 17326029 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine scrub
Number of subjects: 60
Study 17326029 — intervention group
Group type: COMPARATOR
Intervention: Alcohol wash
Number of subjects: 60
Study 17326029 — intervention group
Group type: COMPARATOR
Intervention: Waterless alcohol-chlorhexidine lotion
Number of subjects: 60
Study 16303295 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol 24 microg (2 x 12 microg via Aerolizer)
Number of subjects: 17
Study 16303295 — intervention group
Group type: COMPARATOR
Intervention: salbutamol 600 microg (6 x 100 microg via metered-dose inhaler)
Number of subjects: 17
Study 14557355 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental ostial catheter ablation (SOCA)
Number of subjects: 80
Study 14557355 — intervention group
Group type: COMPARATOR
Intervention: Left atrial catheter ablation (LACA)
Number of subjects: 80
Study 11218985 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 U of intranasal elcatonin (ELC) 2 months ON, 1 month OFF
Number of subjects: 60
Study 11218985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 60
Study 8881638 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide at 0% concentration
Number of subjects: 88
Study 8881638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 20% concentration
Number of subjects: 88
Study 8881638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 40% concentration
Number of subjects: 88
Study 8881638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 60% concentration
Number of subjects: 88
Study 1315646 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (500 micrograms/min)
Number of subjects: 10
Study 1315646 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline infusion
Number of subjects: 10
Study 6384285 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium sulfide (2.5%) lotion applied daily for 10 minutes for 7 consecutive days
Number of subjects: 0
Study 6384285 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 31199744 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA placement over cotton in the pulp chamber and canal orifices (Group 1)
Number of subjects: 40
Study 31199744 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA with RMGI over it (Group 2)
Number of subjects: 40
Study 31199744 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA in canal orifices with RMGI over MTA and pulp chamber floor (Group 3)
Number of subjects: 40
Study 31199744 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA in canal orifices with RMGI over MTA but not on pulpal floor (Group 4)
Number of subjects: 40
Study 30241682 — intervention group
Group type: EXPERIMENTAL
Intervention: RetroMTA
Number of subjects: 22
Study 30241682 — intervention group
Group type: COMPARATOR
Intervention: ProRoot MTA
Number of subjects: 22
Study 27329037 — intervention group
Group type: EXPERIMENTAL
Intervention: 70g dark chocolate (150 mg epicatechin) with placebo capsules
Number of subjects: 20
Study 27329037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure epicatechin capsules (2 × 50 mg epicatechin) with 75g white chocolate
Number of subjects: 20
Study 27329037 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules with 75g white chocolate (0 mg epicatechin)
Number of subjects: 20
Study 24074291 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.01% combined with fluorometholone 0.1%
Number of subjects: 52
Study 24074291 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.01% combined with ketorolac 0.4%
Number of subjects: 52
Study 24074291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 22607938 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ophthalmic tofacitinib 0.005% QD
Number of subjects: 82
Study 22607938 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ophthalmic tofacitinib 0.003% BID
Number of subjects: 82
Study 22607938 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 82
Study 21404880 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intervention
Number of subjects: 385
Study 21404880 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 385
Study 17031690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified cytarabine and idarubicin followed by interferon alfa (IFN-alpha) maintenance
Number of subjects: 118
Study 17031690 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cytarabine and IFN-alpha
Number of subjects: 118
Study 17031690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified cytarabine and idarubicin followed by IFN-alpha maintenance
Number of subjects: 118
Study 17031690 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (allo-SCT)
Number of subjects: 118
Study 16194178 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-ordinated care post-discharge intervention (telephone liaison by Registered Nurse at 2, 6, and 12 weeks)
Number of subjects: 133
Study 16194178 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postoperative telephone contact from Registered Nurse)
Number of subjects: 133
Study 11816046 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 52
Study 11816046 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 52
Study 11816046 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both agents
Number of subjects: 52
Study 10519718 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised training programme and dietary advice (group A)
Number of subjects: 30
Study 10519718 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice alone (group B)
Number of subjects: 30
Study 10519718 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (after one year reassessment)
Number of subjects: 30
Study 7733022 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg fluoxetine/d
Number of subjects: 20
Study 7733022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1936833 — intervention group
Group type: EXPERIMENTAL
Intervention: senna/PEG‐ELS
Number of subjects: 120
Study 1936833 — intervention group
Group type: COMPARATOR
Intervention: PEG‐ELS
Number of subjects: 120
Study 6128740 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg lorazepam orally 1 hour before induction of labour
Number of subjects: 38
Study 6128740 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pre-induction medication)
Number of subjects: 38
Study 31850844 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (catecholamine transporter blocker)
Number of subjects: 102
Study 31850844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 29230987 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression patients (study group)
Number of subjects: 90
Study 29230987 — intervention group
Group type: COMPARATOR
Intervention: Schizophrenics with homicide behavior (control group)
Number of subjects: 90
Study 27884840 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher training, provision of lesson and child-parent interactive homework plans and teaching materials
Number of subjects: 2221
Study 25483480 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV
Number of subjects: 274
Study 25483480 — intervention group
Group type: COMPARATOR
Intervention: SA14-14-2
Number of subjects: 274
Study 22344062 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 24
Study 22344062 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching with motor control exercises for the hip and trunk
Number of subjects: 24
Study 22344062 — intervention group
Group type: EXPERIMENTAL
Intervention: Core endurance with motor control exercises
Number of subjects: 24
Study 22344062 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 19632053 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized gender-specific, parent-involvement intervention program
Number of subjects: 0
Study 19632053 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study 17636179 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (n = 21, group 1)
Number of subjects: 41
Study 17636179 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (n = 20, group 2)
Number of subjects: 41
Study 15770970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m tetrofosmin in ASH
Number of subjects: 28
Study 15770970 — intervention group
Group type: COMPARATOR
Intervention: Tc‐99m tetrofosmin in normal controls
Number of subjects: 28
Study 15770970 — intervention group
Group type: COMPARATOR
Intervention: Comparison of washout rates between ASH and normal controls
Number of subjects: 28
Study 15770970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m tetrofosmin in NYHA II-III patients
Number of subjects: 28
Study 15770970 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of washout with interventricular septum and posterior wall thickness
Number of subjects: 28
Study 11996469 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 85 mg/m2 on day 1 and topotecan 1.5 mg/m2 on days 2-5
Number of subjects: 18
Study 11996469 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 85 mg/m2 on day 1 and topotecan 1.25 mg/m2 on days 2-5
Number of subjects: 18
Study 11996469 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oxaliplatin and topotecan
Number of subjects: 18
Study 11996469 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 85 mg/m2 and topotecan 1.25 mg/m2
Number of subjects: 18
Study 9657583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bennett valve
Number of subjects: 10
Study 9657583 — intervention group
Group type: COMPARATOR
Intervention: Peters valve
Number of subjects: 10
Study 7863934 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg of gadopentetate dimeglumine at 0.5 T
Number of subjects: 0
Study 7863934 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg of gadopentetate dimeglumine at 1.5 T
Number of subjects: 0
Study 7863934 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg of gadodiamide at 0.5 T
Number of subjects: 0
Study 7863934 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg of gadodiamide at 1.5 T
Number of subjects: 0
Study 2592097 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal staples
Number of subjects: 200
Study 2592097 — intervention group
Group type: COMPARATOR
Intervention: Nylon sutures
Number of subjects: 200
Study 1053427 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 129
Study 1053427 — intervention group
Group type: COMPARATOR
Intervention: Close observation for early signs of meningitis
Number of subjects: 129
Study 30633755 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural electric stimulation-guided epidural analgesia
Number of subjects: 62
Study 30633755 — intervention group
Group type: COMPARATOR
Intervention: Loss of resistance technique
Number of subjects: 62
Study 30633755 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural electric stimulation-guided epidural analgesia (only patients without motor blockade)
Number of subjects: 62
Study 30633755 — intervention group
Group type: COMPARATOR
Intervention: Loss of resistance technique (only patients without motor blockade)
Number of subjects: 62
Study 28948663 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO (Experienced Caregivers Helping Others)
Number of subjects: 149
Study 28948663 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 149
Study 28948663 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus ECHO with telephone guidance
Number of subjects: 149